Perrigo Company plc Payments of Debt Issuance Costs
Perrigo Company plc (PRGO) reported Payments of Debt Issuance Costs of $5.50 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-08-05
- Perrigo Company plc payments of debt issuance costs for the quarter ending 2026-06-27 was $0.00.
- Perrigo Company plc payments of debt issuance costs for the quarter ending 2026-03-28 was $5.50M.
- Perrigo Company plc payments of debt issuance costs for the quarter ending 2025-06-28 was $0.00.
- Perrigo Company plc payments of debt issuance costs for the quarter ending 2025-03-29 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month |
|---|---|---|
| 2026-06-27 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.50M 10-Q · filed 2026-08-05 |
| 2026-03-28 | $5.50M 10-Q · filed 2026-05-06 | |
| 2025-06-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 |
| 2025-03-29 | $0.00 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |